Deal Structure Trade Space
Most BD conversations anchor on licensing because that’s the default. But the same asset could be 20–60% more valuable under a different structure — or significantly less. Below are four representative assets run through all five deal structures, ranked by total value to the licensor.
Computed by optimizeDealStructure() (backtest-validated engine). Upfront, milestone allocation, and royalty structures vary by deal type per the DEAL_TYPE_CAPTURE and PHASE_ALLOCATION tables. All figures in $M unless noted otherwise.
Run Your Own Asset
Configure an asset profile below and the engine will rank all five deal structures in real time.
Reference Scenarios
Four representative assets pre-computed for comparison.
Phase 2 oncology mAb
NSCLC, $2B peak, small-biotech licensor
Your asset would be worth 46% more as a Research Collaboration ($182M) than as Licensing ($125M). Based on phase2 oncology benchmarks and your licensor profile, this structure better matches the asset's stage and the typical buyer behavior in this space.
Collaboration
#1Research funding + joint milestones. Early-stage partnership.
Top-ranked: Research Collaboration delivers $182M total deal value with $36M upfront (20% upfront ratio). Best fit for the licensor's risk and cash preferences.
Licensing
#2Upfront + milestones + royalties. Standard bio-pharma template.
Licensing: $125M total — comparable to your selection (within 20%).
Option
#3Small option fee now + larger exercise fee after data. Probability-weighted.
Option / License: $140M total — comparable to your selection (within 20%).
Phase 3 rare disease gene therapy
DMD, $500M peak, orphan designation
Licensing
#1Upfront + milestones + royalties. Standard bio-pharma template.
Top-ranked: Licensing delivers $277M total deal value with $131M upfront (47% upfront ratio). Best fit for the licensor's risk and cash preferences.
Collaboration
#2Research funding + joint milestones. Early-stage partnership.
Research Collaboration: $318M total — comparable to your selection (within 20%).
Option
#3Small option fee now + larger exercise fee after data. Probability-weighted.
Option / License: $188M total — 32% lower than your selection.
Phase 2 immunology bispecific
Atopic dermatitis, $1.5B peak, mid-biotech licensor
Your asset would be worth 23% more as a Research Collaboration ($133M) than as Licensing ($108M). Based on phase2 immunology benchmarks and your licensor profile, this structure better matches the asset's stage and the typical buyer behavior in this space.
Collaboration
#1Research funding + joint milestones. Early-stage partnership.
Top-ranked: Research Collaboration delivers $133M total deal value with $26M upfront (20% upfront ratio). Best fit for the licensor's risk and cash preferences.
Licensing
#2Upfront + milestones + royalties. Standard bio-pharma template.
Licensing: $108M total — comparable to your selection (within 20%).
Option
#3Small option fee now + larger exercise fee after data. Probability-weighted.
Option / License: $125M total — comparable to your selection (within 20%).
Phase 1 platform RNAi
Cardiovascular, $400M peak, early-stage option play
Option
#1Small option fee now + larger exercise fee after data. Probability-weighted.
Top-ranked: Option / License delivers $109M total deal value with $7M upfront (6% upfront ratio). Best fit for the licensor's risk and cash preferences.
Collaboration
#2Research funding + joint milestones. Early-stage partnership.
Research Collaboration: $71M total — comparable to your selection (within 20%).
Licensing
#3Upfront + milestones + royalties. Standard bio-pharma template.
Licensing: $-81M total — comparable to your selection (within 20%).
How we compute this
For each asset, the engine runs calculateRNPV() five times — one per deal type. Peak sales, PoS, discount rate, and cash flow timing are constant across runs; only deal-type-specific upfront / milestone / royalty structure varies. The resulting implied deal values are the headline numbers shown in each card.
Rankings apply a licensor preference profile: clinical-stage biotechs with short cash runway weight cash-now higher, large pharma weights retained upside higher. The profile shifts ties but doesn’t override a meaningfully better headline value.
We surface a recommendation only when the top alternative beats the user’s current structure by ≥20%. Below that threshold, the signal is too weak to override the strategic context (tax, IP, control, relationship dynamics) that drive the choice in practice. This tool informs the conversation; it doesn’t replace it.
Stay Informed
Weekly Deal Intelligence Digest
Get benchmark updates, deal structure shifts, and market intelligence delivered to your inbox.
No spam. Unsubscribe anytime.